Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Songnian Lin is a director of Discovery Chemistry Modalities Group, Merck Research Laboratories, located in Kenilworth, New Jersey, USA. Dr. Lin has a broad research interest including arthritis, diabetes and obesity, hypertension, anemia, and cancer, and has successfully brought multiple drug candidates to various stages of clinical testing. Dr. Lin currently oversees discovery programs on insulin, incretin, and other peptide or conjugation-based efforts. Dr. Lin obtained his PhD from Stony Brook University (advisor: Iwao Ojima) and performed post-doctoral research at the Memorial Sloan-Kettering Cancer Center, New York as an US Army Breast Cancer Research Fellow (advisor: Samuel Danishefsky).